Reduced expression of the MYCBP2 gene has previously been observed in leukemia patients, which has been revealed that CK2 inhibitor takes the anti-leukemia effect through Ikaros-mediated regulation on MYCBP2 expression in high-risk leukemia [46]. The gene discussed is IKZF1; the disease is leukemia.